Adverse reactions after diphtheria-tetanus booster in 10-year-old schoolchildren in relation to the type of vaccine given for the primary vaccination.
This prospective open study investigated adverse reactions in 527 schoolchildren to a diphtheria-tetanus (DT) booster given within a national vaccination programme at 10 years of age. Evaluation was based on those whose immunization records showed that they had received either three doses of an adsorbed DT vaccine (n = 388) or a non-adsorbed DT-pertussis vaccine (DTP) (n = 69) for primary series vaccination. No differences in systemic reactions to the booster between the two groups were observed. Local reactions were significantly (p < 0.001) more common 1 day after vaccination in children who had received DT for primary series vaccination: redness, 73% compared with 23%; swelling, 56% versus 15%; and itching, 47% versus 21%. One and 2 weeks after the booster, itching was still more pronounced in the group who had received DT for primary series vaccination (p < 0.001 and 0.014, respectively). The study indicates that there was a real basis for the increase in spontaneous notifications of local side-effects to the school DT booster in Sweden. The most likely cause for the increase seems to be the aluminium adjuvant in the vaccine given for primary vaccination, a late and unexpected consequence of a change in the infant immunization programme.
Blennow
M
M
Department of Pediatrics, Sachs' Children's Hospital, Stockholm, Sweden.
Granström
M
M
Strandell
A
A
D000276:Adjuvants, Immunologic / Q000009:adverse effects*; D017607:Aluminum Compounds / Q000009:adverse effects*; D002648:Child; D004168:Diphtheria Toxoid / Q000009:adverse effects*; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D004487:Edema / Q000139:chemically induced; D004890:Erythema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000009:adverse effects*; D008297:Male; D009313:National Health Programs; D010710:Phosphates / Q000009:adverse effects*; D011446:Prospective Studies; D011537:Pruritus / Q000139:chemically induced; D013548:Sweden; D013745:Tetanus Toxoid / Q000009:adverse effects*; D014611:Vaccination
D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds; D004168:Diphtheria Toxoid; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D010710:Phosphates; D013745:Tetanus Toxoid; C012714:aluminum phosphate